Management of childhood psoriasis in France. A national survey among general practitioners, pediatricians, and dermatologists

Dermatol Ther. 2018 Jan;31(1). doi: 10.1111/dth.12567. Epub 2017 Nov 28.

Abstract

Psoriasis affects 0.5-2% of children. Severe forms required use of systemic treatments. Few studies are published on efficiency and tolerance of systemic treatments in children. We conducted a survey in France to better understand management of children with psoriasis. A survey on childhood psoriasis management was sent by e-mail to GPs, pediatricians, and dermatologists. The survey included 384 physicians. Respectively 53.1%, 49.8%, and 83.3% of GPs, pediatricians, and dermatologists declare to have seen at least one child with psoriasis during the 3 previous months. Less than 5% of GPs and pediatricians used severity score versus 23.7% of dermatologists. If most of physicians declare to use local treatments, less than 5% of GPs and pediatricians used systemic treatments. 32.4% of dermatologists declared to use at least one systemic treatment, but only 2.9% to use the 4 systemic treatments available in France. This survey shows that only half of GPs and pediatricians see children with psoriasis, but most of dermatologists. However, the management of severe forms seems limited by the underuse of severity scores and systemic treatments. These results should stimulate dermatology societies to promote prospective studies and guidelines in young populations with psoriasis.

Keywords: adolescent; child; psoriasis; severity index; therapeutics.

MeSH terms

  • Adult
  • Age of Onset
  • Child
  • Child, Preschool
  • Clinical Decision-Making
  • Dermatologic Agents / adverse effects
  • Dermatologic Agents / therapeutic use*
  • Dermatologists / trends*
  • Female
  • France / epidemiology
  • General Practitioners / trends*
  • Health Care Surveys
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Pediatricians / trends*
  • Practice Patterns, Physicians' / trends*
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Psoriasis / epidemiology
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome

Substances

  • Dermatologic Agents